Positive Clinical Data Presented For Lead Accurin Candidate BIND-014 In Cancer Patients

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, has announced that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented in an oral presentation at the American Association for Cancer Research (AACR) 2013 Annual Meeting. Clinical investigators presented the Phase 1 results with BIND-014, its targeted docetaxel Accurin, in 28 heavily-pretreated patients with advanced or metastatic solid tumors...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/8YVgZL7AyeA/258899.php

auto sport medical rehab